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Abstract
Background: Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting
high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has
been the unavailability and costs of HPV DNA-based testing. This study compares the performance of careHPV,
a semi-rapid and affordable qualitative detection assay for 14 hr-HPV genotypes, with HPV genotyping, for the
detection of cytological cervical squamous intraepithelial lesions (SIL).
Methods: A study comparing between frequency matched HIV-1 seropositive and HIV-seronegative women was
conducted in the Cape Coast Teaching Hospital, Ghana. A systematic sampling method was used to select women
attending clinics in the hospital. Cervical samples were tested for HPV by careHPV and Anyplex-II HPV28 genotyping
assay, and by conventional cytology.
Results: A total of 175 paired results (94 from HIV-1 seropositive and 81 from HIV-seronegative women) were
analyzed based on the ability of both tests to detect the 14 hr-HPV types included in the careHPV assay. The
inter-assay concordance was 94.3% (95%CI: 89.7–97.2%, kappa = 0.88), similar by HIV serostatus. The careHPV
assay was equally sensitive among HIV-1 seropositive and seronegative women (97.3% vs. 95.7%, p = 0.50) and slightly
more specific among HIV-seronegative women (85.0% vs. 93.1%, p = 0.10). careHPV had good sensitivity (87.5%) but
low specificity (52.1%) for the detection of low SIL or greater lesions, but its performance was superior to genotyping
(87.5 and 38.8%, respectively). Reproducibility of careHPV, tested on 97 samples by the same individual was 82.5%
(95%CI: 73.4–89.4%).
Conclusions: The performance characteristics of careHPV compared to genotyping suggest that this simpler and
cheaper HPV detection assay could offer a suitable alternative for HPV screening in Ghana.
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Background
Persistent infection with high-risk oncogenic human pap-
illomavirus (hr-HPV) genotypes is aetiologically linked
with cervical cancer and its precursor histological cervical
intraepithelial neoplasia (CIN) or cytological squamous
intraepithelial lesions (SIL) [1, 2]. Modern cervical cancer
screening increasingly relies on the use of HPV testing in
developed countries because of its high sensitivity to
detect CIN/SIL [3, 4]. Resource intensive molecular
methods, such as genotyping using polymerase chain
reaction (PCR) are able to detect and type HPV but are
mostly unavailable in developing countries like Ghana.
However, simplified molecular assays are becoming
available which will enable HPV molecular diagnosis in re-
source-constrained settings. The careHPV assay (Qiagen,
Gaithersburg, MD), a simplified version of the better
known Digene Hybrid Capture 2 (HC2), has shown prom-
ise with high sensitivity and specificity against histological
end points when tested in diverse setting and heterogeneou
populations as Africa and China [5–7]. A study conducted
among 149 women living with HIV in Burkina Faso and
South Africa was the first head to head evaluation of car-
eHPV versus HC2 among African women and reported an
excellent agreement between the two tests (94.6%, 95%
confidence interval [CI]: 89.7 to 97.7%, Kappa value = 0.88)
and concluded that careHPV assay could be as suitable as
HC2 for cervical cancer screening among HIV-infected
African women [6].
In Ghana, HPV testing has remained confined to re-
search laboratories where genotyping is used. One such
genotyping assay is the recently developed AnyplexTM II
HPV28 (Seegene, Seoul, Korea). The assay detects 28
HPV genotypes including 19 hr-HPV types of which 13
are considered carcinogenic (HPV16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68), six possible carcinogenic
(HPV26, 53, 66, 69, 73 and 82), and nine low-risk HPV
types (HPV6, 11, 40, 42, 43, 44, 54, 61 and 70), accor-
ding to the Interagency for Research on Cancer (IARC)
classification [8]. The addition of a high performing,
semi-rapid and affordable test such as careHPV would
considerably enhance access to HPV-based cervical
cancer screening in the country. In particular, since HPV
molecular assays have very high negative predictive value
for the detection of cervical cancer lesions, they could
become very useful as a primary screening test or as
triage in combination with cytology. However, because
they cannot distinguish between transient and persistent
infections, their specificity is low. They are thus recom-
mended for use among women aged 30 years and older
when most HPV infections should have cleared. Molecu-
lar tests can also indicate complete viral eradication if
the result is negative 12 months following cervical
lesions treatment, hence they can be useful for patients’
follow-up. Studies have compared various strategies
including those which combine HPV genotyping with
concurrent cytology and those which offer HPV screening
without concurrent cytology. The results of the ATHENA
trial conducted among 42,209 women in the United States
of America comparing various single or combination
screening strategies suggest that both strategies are
feasible and have equivalent performance depending on
factors like age of the woman [9]. Other important factors
in selecting a particular screening strategy include its abil-
ity to restrict the number of unnecessary colposcopies
while maintaining a high negative predictive value [7, 10].
The present study aimed at comparing careHPV with
HPV genotyping for the molecular diagnosis of HPV and
at evaluating the performance of both assays against cy-
tology among HIV-1 seropositive and HIV-seronegative
women in Ghana. This is an essential step as the country
is looking to inform the development of its cervical cancer
screening algorithms.
Methods
Study design and subjects
Participants were recruited as part of a larger HPV/cer-
vical cancer epidemiological study (comparing HIV-1
seropositive to HIV-seronegative women) conducted in
the Cape Coast Teaching Hospital (CCTH) in Ghana.
Briefly, a comparative frequency-matched study was con-
ducted in a systematic (1 in 5) sample of women attending
the HIV and the general outpatient clinics at CCTH. Every
fifth woman aged ≥18 years was systematically selected
from the list of attendants, starting by a randomly selected
attendance number for the first woman. If a woman was
deemed not eligible (i.e. who had previous total abdominal
hysterectomy, was menstruating that day, or was
pregnant), the next available patient was offered her
place, and every fifth woman whence, to a maximum
of 10 women per clinic day. Participants who met the
inclusion criteria (i.e. aged ≥18 years and willing to
be tested for HIV) were given an explanation of the
protocol after which written informed consent was
obtained. This method was used to recruit the women
for the parent study and then a sub set target of
about 50% of participants (every other recruited
woman) were asked to be part of the careHPV
evaluation study.
Clinical sample collection
Gynaecological examination with speculum was per-
formed, during which cervical swabs were collected from
the ecto and endocervix targeting the squamo-columnar
junction using a DNA PAPTM Cervical SamplerTM and
transported in Swab Specimen Collection Kit (Qiagen,
Gaithersburg, MD) for genotyping by Anyplex II HPV
28. For careHPV testing, the careHPV specific brush and
transport medium were used (Qiagen, Gaithersburg,
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MD). Cervical smears were taken for cytology with a cer-
vical brush and immediately alcohol-fixed at the clinic.
HPV DNA detection
The Anyplex II HPV 28 test was performed from its spe-
cific transport medium as per manufacturer’s protocol
previously described [11]. The isolation of nucleic acid
was by QIAamp DNA Mini kit (Qiagen, USA) as per
established protocol by the manufacturer using 500 μl of
the sample. The process from DNA extraction to the
RT-PCR for a full panel of 96 plate takes at least 6 h to
complete. The careHPV test was performed on the sam-
ples collected into the careHPV transport medium. This
test is a semi-rapid test designed based on simplification
of the Digene HC2 test technology to be used for the de-
tection of the DNA for 14 hr-HPV types (HPV16, 18,
31, 33, 35, 39, 45, 52, 56, 58, 59, 66 and 68; HPV66 being
the addition). This test takes 2.5 to 3 h to perform for a
96 well and involves 6 easy-to-follow steps of denatur-
ation, hybridization and capturing, conjugation, washing,
additions of substrate and detection with the illumin-
ometer. The results obtained are qualitative for hr-HPV
without indicating the specific genotype [7, 12, 13]. In
order to verify testing reproducibility, a random 50% of
samples were retested without knowledge of prior result.
Cervical cytology
Cervical smears were prepared in the laboratory follow-
ing a standardized protocol for Papanicolaou (Pap) stain-
ing. Slides were read by a consultant cytopathologist at
CCTH using the Bethesda 2001 guidelines for SIL classi-
fication [14].
Statistical analysis
Analysis of careHPV performance compared with geno-
typing was done for 14 hr-HPV genotypes detectable by
both tests (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66 and 68). Sensitivity, specificity, positive and negative
predictive values (PPV and NPV), and Cohen’s Kappa
values for agreement between the two tests were
calculated with their 95%CI. These were calculated for the
total results and then also done separately for HIV-1 sero-
positive and HIV-seronegative women separately. Data
analyses were performed using Stata version 13 software
(Stata Corp, Texas USA).
Ethics
Ethical approval for this study was obtained from the
Committee on Human Research Publications and Ethics
(CHRPE) of the School of Medical Sciences (SMS),
Kwame Nkrumah University of Science and Technology
(KNUST) before the study commenced. Study partici-
pants were recruited only after obtaining signed written
informed consent.
Results
Overall, 333 eligible women were included in the parent
study, 163 HIV-1 seropositive women (mean age
43.8 years, standard deviation [SD] ±9.4) and 170 HIV-
seronegative women (mean age 44.3 years, SD ±12.8). A
total of 197 paired careHPV and genotyping samples
from the subsample of women (100 HIV-1 seropositive
(mean age 44.7 years, SD ±9.7) and 97 HIV-seronegative
(mean age 43.7 years, SD ±12.8) randomly selected into
the careHPV validation study were tested, and 175
results (89%) were available for analysis based on the
ability of both tests to detect the 14 hr-HPV types. For
21 careHPV results (6 from HIV-1 seropositive and 15
from HIV-seronegative women), Anyplex II HPV 28
detected genotypes which are undetectable by careHPV
(i.e., low-risk types, as well as HPV26, 53, 69, 73 and
82). In addition, one careHPV sample (from an HIV-
seronegative woman) gave an invalid result despite
repeat testing. These 22 samples (11.1%) were not
included in the analysis of careHPV performance.
The hr-HPV prevalence by careHPV was 55% (95%CI:
48.0–62.9) overall, 79% (95%CI: 69.0–86.5) among HIV-1
seropositive women and 28.0% (95%CI: 19.0–39.5) among
HIV-seronegative women (p ≤ 0.0001) (Table 1). Similarly,
the hr-HPV prevalence by genotyping was 57% (95%CI:
49.0–64.0), 79% (95%CI: 69.0–86.5) among HIV-1
seropositive women and 31% (95%CI: 12.0–42.1) among
HIV-seronegative women (p ≤ 0.0001).
There was excellent agreement (94.3%, 95%CI:
89.7–97.2%) between careHPV and genotyping overall
(kappa = 0.88, 95%CI: 0.81–0.95, p < 0.0001), and the
agreement was similar among HIV-1 seropositive
(94.7%, 95%CI: 88.0–98.3%) and seronegative (93.8%,
95%CI: 86.2–98.0%) women (Kappa of 0.84 and 0.85,
respectively) (Table 1). The careHPV assay was
equally sensitive among HIV-1 seropositive and HIV-
seronegative women (97.3% vs. 95.7%, p = 0.50) and
slightly more specific among HIV-seronegative women
(85.0% vs. 93.1%, p = 0.10), but these differences were
not statistically significant (Table 1).
For 9 of the hr-HPV types (HPV18, 31, 33, 35, 39, 45,
51, 52 and 68), the concordance between careHPV and
Anyplex II HPV 28 was 100%. For 4 genotypes careHPV
missed one positive sample, and for HPV58 it missed 2
samples (Table 2).
careHPV prevalence increased according to severity of
cytological lesions, from 47.8% among women with
normal cytology to 100% among women with high-grade
lesions (HSIL/ASC-H) (p-trend = 0.08). Similarly, hr-
HPV prevalence by genotyping increased by cytological
grade severity (p-trend = 0.07) (Fig. 1). careHPV and geno-
typing had the same sensitivity for detection of lesions low
SIL and above of 87.5% (95%CI: 43.3–99.7%) but careHPV
had statistically significantly higher specificity (52.1% vs.
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38.8%, 95%CI: 31.8–46.2%, p < 0.0001), PPV and NPV than
genotyping (Table 3).
A random sample of approximately 50% of all careHPV
samples was tested twice by the same individual with car-
eHPV to check the reproducibility of results. Of these, 80/
97 produced the same results giving a reproducibility rate
of 82.5% (95%CI: 73.4–89.4%). In 5/97 initially negative
careHPV results the second result was positive, 2/97
became invalid and in 8/97 positive careHPV result, the
second result was negative, and 2 became invalid.
Discussion
Given the high cost and resource intensive nature of
genotyping for HPV screening, both in terms of skills
and materials, it is essential that developing countries
find acceptable alternatives to move into the modern
cervical cancer screening era. The advantage of full
genotyping is its higher analytical sensitivity and ability
to specifically identify the genotypes present in a popula-
tion. While this is essential for research or epidemio-
logical monitoring purposes, it is not absolutely
necessary for clinical care. The role of HPV screening
for clinical practice is to help establish a protocol of
screening which is cost effective and helps identify
women having hr-HPV infection so they can have
further evaluation [7], whilst helping reduce the number
of unnecessary colposcopies and histology. Since
molecular testing of HPV does not necessarily require
representative samples from the cervix to be taken, an
additional potential benefit is the possible use of self-
collected vaginal samples. This might increase testing by
women especially in settings where self-collection might
be preferred either due to cultural reasons or the
convenience of not necessarily having to visit a health
facility to provide samples [15–17]. Full genotyping
requires DNA extraction (an additional cost) and
molecular testing. Samples for DNA extraction for PCR
have strict temperature control: they must be immedi-
ately extracted or kept in a fridge, and once extracted
the DNA must be stored at 20 °C until used. Both DNA
extraction and PCR testing require extensive technical
training and appropriate setup. There is also the need to
ensure continuous supply of electrical power throughout
the processing until results are generated. All of these
factors pose a tremendous challenge for resource-
constrained countries like Ghana.
careHPV represents an alternative HPV screening
assay that has been specifically developed for resource-
constrained settings. This assay requires just bench top
and 3 portable equipment which has a backup battery to
store power enough to run a full set of 96 samples with-
out the need for an external supply of electricity. The
samples for careHPV can also be stored at room
temperature for up to 4 weeks, do not require DNA
Table 1 Performance characteristics of careHPV assay for the detection of 14 high-risk (hr) HPV genotypes compared with HPV
genotyping among 175 women in Cape Coast, Ghana
All women (N = 175)
% (95% CI)
HIV-1 seropositive women (N = 94)
% (95% CI)
HIV seronegative women (N = 81)
% (95% CI)
*P-value
hr-HPV prevalence 55.0 (48.0–62.9) 79.0 (69.0–86.5) 28.0 (19.0–39.5) 0.0001
Sensitivity 96.9 (91.2–99.4) 97.3 (90.6–99.7) 95.7 (78.1–99.9) 0.50
Specificity 91.0 (82.4–96.3) 85.0 (62.1–96.8) 93.1 (83.3–98.1) 0.10
PPV 93.1 (86.2–97.2) 96.0 (88.8–99.2) 84.6 (65.1–95.6) 0.01
NPV 95.9 (88.8–99.2) 89.5 (66.9–98.7) 98.2 (90.3–100.0) 0.02
Agreement 94.3 (89.7–97.2) 94.7 (88.0–98.3) 93.8 (86.2–98.0) 0.77
Kappa value (95%CI) 0.88 (0.81–0.95) 0.84 (0.70–0.98) 0.85 (0.73–0.98) 0.86
P-value for Kappa <0.0001 <0.0001 <0.0001
PPV positive predictive valuem, NPV negative predictive value
* comparing HIV-1 seropositive and HIV-seronegative women
Table 2 Agreement between results of careHPV and genotyping
with Anyplex II HPV28 for the detection of 14 high-risk HPV
genotypes, among 175 women in Cape Coast, Ghana
HPV genotypes Anyplex II HPV28
No. Positive (%)
careHPV
No. Positive (%)
Agreement %
16 15 (8.6) 14 (8.0) 93.3
18 15 (8.6) 15 (8.6) 100.0
31 13 (7.4) 13 (7.4) 100.0
33 12 (6.9) 12 (6.9) 100.0
35 17 (9.7) 17 (9.7) 100.0
39 8 (4.6) 8 (4.6) 100.0
45 8 (4.6) 8 (4.6) 100.0
51 1 (0.6) 1 (0.6) 100.0
52 16 (9.1) 16 (9.1) 100.0
56 12 (6.9) 11 (6.3) 91.7
58 20 (11.4) 18 (10.3) 90.0
59 6 (3.4) 5 (2.9) 83.3
66 7 (4.0) 6 (3.4) 85.7
68 12 (6.9) 12 (6.9) 100.0
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extraction and require very limited technical knowledge
to be performed. While careHPV has been evaluated in
some settings, this research presents the first such evalu-
ation done among women including HIV seropositive
and seronegative women in Ghana. The simplicity of the
assay and its relative robustness in the context of a
resource-constrained laboratory setting was confirmed
in this study. Various studies have been conducted using
this assay including in Uganda [12], rural China [18],
rural Thailand [19] with good outcomes.
This study found an excellent agreement (94.3%, k = 0.88)
between careHPV and full HPV genotyping for the detec-
tion of 14 hr-HPV genotypes, and the result was similar
among HIV-1 seropositive and HIV-seronegative women.
The careHPV assay was slightly more sensitive among
HIV-1 seropositive women but more specific among HIV-
seronegative women. Investigators in Burkina Faso and
South Africa found very similar excellent agreement
(94.6%) for careHPV compared to HC2 [6], a well-validated
HPV qualitative assay used in many settings, and when
compared to genotyping using the InnoLiPA assay [20].
The clinical performance though not extensively investi-
gated in this study was good as careHPV detected 83.3% of
all cases with LSIL and all cases (100%) of HSIL/ASC-H.
Other studies have demonstrated good clinical performance
of careHPV in HIV-seronegative African women [21] and
in African women living with HIV-1. Segondy et al. [20]
found the sensitivity and specificity of careHPV for the
diagnosis of HSIL among 929 HIV-1 seropositive women
in Burkina Faso and South Africa to be 88.8 and 61.8%
respectively. The negative predictive value of careHPV for
detection of cytological lesions was 99.0% in this study. This
is very important because it implies that it could serve as
an essential screening tool. Given its good sensitivity but
low specificity, careHPV testing might be best performed as
triage test with cytology or visual inspection (VIA) to
reduce unnecessary referrals for colposcopy. It will be
useful to study the cost effectiveness of such strategies in
the Ghanaian socio-economic context.
To check reproducibility and hence reliability of re-
sults, 97 samples were tested in duplicate in this study
by the same individual. Reproducibility was found to be
82.5%. This is good but still implies that all of the 6
processing steps be completed without fault by a meticu-
lous lab technician to reduce the risk of having variable
results, and that quality control should be routinely
implemented. The positive and negative controls
included for each plate serve to ensure that only valid
Fig. 1 14 hr-HPV prevalence by careHPV and genotyping according to cytological findings among women, Cape Coast, Ghana. Cytology readings:
Normal = no abnormal findings found; ASCUS = atypical squamous cells of undetermined significance; LSIL = low grade squamous intraepithelial
lesions; HSIL = high grade squamous intraepithelial lesions; ASC-H = Atypical squamous cells cannot rule out HSIL. Hr-HPV = high risk HPV types
Table 3 Performance of careHPV and genotyping to detect cases of cytological abnormalities (LSIL and greater, n = 8) among 197
study participants in Cape Coast, Ghana
Performance Indicators careHPV
% (95%CI)
Anyplex II HPV 28
% (95%CI)
Number of LSIL+ cases detected by assay 7 7
Sensitivity 87.5 (47.3–99.7) 87.5 (47.3–99.7)
Specificity 52.1 (44.7–59.5) 38.8 (31.8–46.2)
Positive predictive value (PPV) 7.2 (3.0–14.3) 5.7 (2.3–11.5)
Negative predictive value (NPV) 99.0 (94.5–100.0) 98.6 (92.7–100.0)
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results are read, and only a small proportion of retests we
found invalid (4%). To assess the reliability of results in a
study evaluating careHPV assay in Nigeria, researchers
checked intra-rater (reproducibility of results by the same
local technician) and inter-rater (reproducibility of results
between 2 different local technicians) agreements. Intra-
rater agreement was 98.8% (k = 0.97) and 98.9% (k = 0.97)
for Technicians 1 and 2, respectively, and the inter-rater
agreement was 96.3% (k = 0.90), suggesting that careHPV
results were reliable [5], which is very encouraging for
countries in the region. However, the higher agreement
values found in the Nigerian study suggest that this can
also be very dependent on locale/staff.
The present study had some limitations. The number
of samples tested by careHPV was relatively low, owing
to financial constraints and dependence on donated car-
eHPV kits; and for the same reasons a more extensive
repeat testing could not be organized. Furthermore, a
full economic evaluation of cervical cancer screening
was beyond the scope of this study. However, based on
market prices and personal communication with rele-
vant people, the cost of genotyping (including reagents
and technician time) would come to approximately US$
100.00 per sample, whereas careHPV cost could be
about US$ 15–20.00 per sample. Other forms of cervical
screening include cytology (Pap smears) being offered at
a minimum of US$ 15.00 in Ghana (personal communi-
cation from facilities offering these tests), whereas visual
inspection using VIA could cost as little as US$ 5.00 (up
to US$ 15) [22]. As indicated by the study by Quentin et
al., the feasibility of increasing uptake to achieve econ-
omies of scale in Ghana is essential for choosing a
screening method [22]. The fact that HPV-based screen-
ing protocols can increase screening intervals [23, 24]
and allow for possible patient self-collection [25] are im-
portant advantages that could reduce costs and increase
access for both health services and Ghanaian women.
Conclusion
This study has demonstrated that careHPV has very
good concordance with, and good performance charac-
teristics compared to, HPV genotyping for the detection
of cervical squamous intraepithelial lesions, and whilst
reproducibility could be improved, the findings support
the possibility of setting up HPV screening without the
need for resource-intensive genotyping as a suitable
alternative for cervical cancer screening in countries like
Ghana.
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